Year End Statement of Thomas Klein, Founder & CEO of Pirche

Pirche's Year of Achievement and Growth

Year end statement of Thomas Klein, Founder & CEO of Pirche:

As 2024 concludes, I'm excited to share Pirche's incredible journey! Our team has achieved remarkable milestones, and I'm immensely proud of their dedication and hard work.

🚀 Key Highlights:

• TxPredictor Launch: Our groundbreaking platform analyzes both T- and B-cell epitope levels, providing comprehensive patient risk profiles unmatched by any other platform. This means more precise matching and better outcomes for transplant patients.  
• Strong Pre-Transplant Pipeline: We're thrilled to be collaborating with major transplant centers, and many more SaaS agreements with leading clinics in progress.  
• Groundbreaking Post-Transplant Model: We're revolutionizing post-transplant monitoring, partnering with service providers to enhance clinical decision-making and improve patient care.  
• Industry Leadership: Our exceptional team is committed to establishing Pirche as the gold standard in pre- and post-transplant risk assessment and decision support.  

🤝 Supporting the US Healthcare System
We're proud to align our business development with the Increased Organ Transplant Access (IOTA) initiative, a vital US government program for transplant medicine. Our innovative scoring system plays a crucial role in increasing organ availability for patients in need.  

💡 Looking Ahead to 2025
We're committed to expanding our commercial presence and establishing Pirche as the industry leader. We'll continue investing in research and development to enhance our technology and expand our platform's capabilities.

🙏 Thank You!
I'm filled with optimism for the future and grateful for your incredible support. Together, we're transforming transplant care!

#transplantinnovation #healthcaretechnology #Pirche #TxPredictor #IOTA